JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Osimertinib dimesylate (formerly known as AZD-9291 dimesylate and mereletinib dimesylate) is a novel, potent, oral bioavailable, irreversible, and mutant-selective, 3rd generation EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. It was approved as a cancer treatment in 2017 by both the Food and Drug Administration and the European Commission.
References: Transl Lung Cancer Res. 2014 Dec; 3(6):370-2; J Med Chem. 2014 Oct 23; 57(20):8249-67.
Related CAS: 1421373-66-1 (mesylate); 1421372-66-8 (AZD9291 DA - the des acryl derivative of AZD9291); 1421373-66-1 (mesylate)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!